

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
X: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © European Alliance of Associations for Rheumatology, EULAR 2024. Published by BMJ. All rights reserved.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Viewpoint

- 409** Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
K L Winthrop, P Mease, A Kerschbaumer, RE Voll, F C Breedveld, J S Smolen, J-E Gottenberg, X Baraliakos, H P Kiener, D Aletaha, J D Isaacs, M H Buch, M K Crow, J Kay, L Crofford, R F van Vollenhoven, C Ospelt, S Siebert, M Kloppenburg, I B McInnes, T WJ Huizinga, E M Gravallese

Heroes and pillars of rheumatology

- 417** Morris Ziff
P Cohen, D Ziff, P E Lipsky

Rheumatoid arthritis

- 421** Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)
R Aymon, D Mongin, S A Bergstra, D Choquette, C Codreanu, D De Cock, L Dreyer, O Elkayam, D Huschek, K L Hyrich, F Iannone, N Inanc, L Kearsley-Fleet, S S KOCA, T K Kvien, B F Leeb, G Lukina, D C Nordström, K Pavelka, M Pombo-Suarez, A Rodrigues, Z Rotar, A Strangfeld, P Verschuere, R Westermann, J Zavada, D S Courvoisier, A Finckh, K Lauper
- 429** Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis
J F Baker, J R O'Dell, B R England, J T Giles, J A Newcomb, M D George, G Thiele, L Moreland, S L Bridges, J R Curtis, T R Mikuls

- 437** Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial
M M H Teuwen, S F E van Weely, T P M Vliet Vlieland, M A T van Wissen, W F Peter, A A den Broeder, D van Schaardenburg, W B van den Hout, C H M Van den Ende, M G J Gademan

Psoriatic arthritis

- 446** Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study
S Exarchou, D Di Giuseppe, E Klingberg, V Sigurdardottir, S Wedrén, U Lindström, C Turesson, L T H Jacobsson, J Askling, J K Wallman

Inflammatory arthritis

- 457** Male patients with inflammatory joint diseases are less likely than controls to be childless: results from a Norwegian population-based cohort study of 10 865 patients
G D Sigmo, S Hauge, K O Hufthammer, M Wallenius, K Å Salvesen, A K N Daltveit, G Bakland, B-T S Fevang

Systemic lupus erythematosus

- 464** Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression
S Pitsigavdaki, M Nikoloudaki, P Garantziotis, E Silvagni, A Repa, A Marangoni, I Flouri, N Avgoustidis, K Parperis, A Fanouriakis, M Govoni, P Sidiropoulos, D T Boumpas, A Bortoluzzi, G Bertias

- 475** Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
D Wu, J Li, D Xu, J T Merrill, R F van Vollenhoven, Y Liu, J Hu, Y Li, F Li, C Huang, G Wang, X Li, J Zhao, D Zhao, C Huang, H Liu, W Wei, G Shi, F Lu, X Zuo, L Bi, Z Li, X Wang, M Zhang, N Tie, J Li, H Mo, J Fang, C Bao, F Zhang

Systemic sclerosis

- 488** CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for selective cell depletion
T I Papadimitriou, P Singh, A van Caam, B Walgreen, M A J Gorris, E L Vitters, I L van Ingen, M I Koenders, R L Smeets, M Vonk, J M de Vries, P M van der Kraan, Y van Oosterhout, M A Huynen, H J P M Koenen, R M Thurlings

Vasculitis

- 499** CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury
D Lodka, M Zschummel, M Bunse, A Rousselle, J Sonnemann, R Kettritz, U E Höpken, A Schreiber

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>



Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 508** Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis
F Gutierrez-Rodriguez, K V Wells, A I Jones, D Hironaka, C Rankin, M Gadina, K A Sikora, L Alemu, R T Calado, K A Quinn, B Patel, N S Young, P C Grayson

Animal models

- 518** Bona fide dendritic cells are pivotal precursors for osteoclasts
A Puchner, E Simader, V Saferding, M Hofmann, M Kieler, J Brunner, R Pfeifle, B Niederreiter, G Krönke, G Schabbauer, P Georgel, G Diehl, G Steiner, S Hayer, K Redlich, J S Smolen, D Aletaha, S Blüml

Miscellaneous

- 529** Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget's disease of bone
J Phillips, D Subedi, S C Lewis, C Keerie, O Cronin, M Porteous, D Moore, R Cetnarskyj, L Ranganath, P L Selby, T Turgut, G Hampson, R Chandra, S Ho, J Tobias, S Young-Min, M J McKenna, R K Crowley, W D Fraser, J C Y Tang, L Gennari, R Nuti, M L Brandt, J Del Pino-Montes, J-P Devogelaer, A Durnez, G C Isaia, M Di Stefano, N Guanabens, J Blanch Rubio, M J Seibel, J P Walsh, S L Rea, M A Kotowicz, G C Nicholson, E L Duncan, G Major, A Home, N Gilchrist, S H Ralston

Images in rheumatology

- 537** IgG4-related tubulointerstitial nephritis
M-K Tsai, Y-L Chen, H-C Chen, F-C Liu, D-M Chang, C-C Lu

Letters

- 540** Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study
V Melokhina, N Paulshus Sundlisæter, J Sexton, U Sundin, A-B Aga, K E Kjørholt, L B Nordberg, D van der Heijde, E Haavardsholm, S Lillegraven
- 541** Low plasma belimumab levels as an indicator of poor adherence to belimumab in patients with systemic lupus erythematosus
L Trefond, N Zahr, R Lhote, M Pha, M Hié, M Miyara, M Papo, Q Moyon, P Hausfater, F Chasset, J Haroche, F Cohen-Aubart, A Mathian, Z Amoura
- 543** Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
W Merkt, M Freitag, M Claus, P Kolb, V Falcone, M Röhrich, L Rodon, F Deicher, I Andreeva, T Tretter, L-O Tykocinski, N Blank, C Watzl, A Schmitt, T Sauer, C Müller-Tidow, M Polke, C P Heußel, P Dreger, H-M Lorenz, M Schmitt



OPEN ACCESS



OPEN ACCESS